Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
用户EO9nReo4Hj6s
1个月前
119
10
已完结
1. 系统已在2026-09-11 14:42:41对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s10549-026-08066-5
文献链接: https://link.springer.com/10.1007/s10549-026-08066-5
其他信息:
出版社: Springer Science and Business Media LLC
作者: Zhenluan Tian; Hengyu Li; Yuxin Deng; Herui Yao; Ying Wang; Liang Jin; Heran Deng; Na Chen; Jieqiong Liu
全文下载地址: https://link.springer.com/content/pdf/10.1007/s10549-026-08066-5.pdf
